已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Panitumumab-DOTA-111In: An Epidermal Growth Factor Receptor Targeted Theranostic for SPECT/CT Imaging and Meitner–Auger Electron Radioimmunotherapy of Triple-Negative Breast Cancer

放射免疫疗法 多塔 三阴性乳腺癌 癌症研究 化学 表皮生长因子受体 医学 肿瘤科 核医学 癌症 乳腺癌 内科学 单克隆抗体 免疫学 抗体 螯合作用 有机化学
作者
Valerie J. Facca,Zhongli Cai,Nakita E. K. Gopal,Raymond M. Reilly
出处
期刊:Molecular Pharmaceutics [American Chemical Society]
卷期号:19 (10): 3652-3663 被引量:14
标识
DOI:10.1021/acs.molpharmaceut.2c00457
摘要

Epidermal growth factor receptors (EGFR) are overexpressed in triple-negative breast cancer (TNBC) and are an attractive target for the development of theranostic radiopharmaceuticals. We studied anti-EGFR panitumumab labeled with 111 In (panitumumab-DOTA- 111 In) for SPECT/CT imaging and Meitner–Auger electron (MAE) radioimmunotherapy (RIT) of TNBC. Panitumumab-DOTA- 111 In was bound, internalized, and routed to the nucleus in MCF7, MDA-MB-231/Luc, and MDA-MB-468 human breast cancer (BC) cells dependent on the EGFR expression level (1.5 × 10 4, 1.7 × 10 5, or 1.3 × 10 6 EGFR/cell, respectively). The absorbed dose in the nuclei of MCF7, MDA-MB-231/Luc, and MDA-MB-468 cells incubated with 4.4 MBq of panitumumab-DOTA- 111 In (20 nM) was 1.20 ± 0.02, 2.2 ± 0.1, and 25 ± 2 Gy, respectively. The surviving fraction (SF) of MDA-MB-231/Luc cells treated with panitumumab-DOTA- 111 In (10–300 nM; 1.5 MBq/μg) was reduced as the absorbed dose in the cell increased, with clonogenic survival reduced to an SF = 0.12 ± 0.05 at 300 nM corresponding to 12.7 Gy. The SFs of MDA-MB-468, MDA-MB-231/Luc, and MCF7 cells treated with panitumumab-DOTA- 111 In (20 nM; 1.7 MBq/μg) were <0.01, 0.56 ± 0.05, and 0.67 ± 0.04, respectively. Unlabeled panitumumab had no effect on SF, and irrelevant IgG-DOTA- 111 In only modestly reduced the SF of MDA-MB-231/Luc cells but not MCF7 or MDA-MB-468 cells. The cytotoxicity of panitumumab-DOTA- 111 In was mediated by increased DNA double-strand breaks (DSB), cell cycle arrest at G2/M-phase and apoptosis measured by immunofluorescence detection by flow cytometry. MDA-MB-231/Luc tumors in the mammary fat pad (MFP) of NRG mice were clearly imaged with panitumumab-DOTA- 111 In by microSPECT/CT at 4 days postinjection (p.i.), and biodistribution studies revealed high tumor uptake [18 ± 2% injected dose/g (% ID/g] and lower normal tissue uptake (<10% ID/g). Administration of up to 24 MBq (15 μg) of panitumumab-DOTA- 111 In to healthy NRG mice caused no major hematological, renal, or hepatic toxicity with no decrease in body weight. Treatment of NOD SCID mice with MDA-MB-231 tumors with panitumumab-DOTA- 111 In (22 MBq; 15 μg) slowed tumor growth. The mean time for tumors to reach a volume of ≥500 mm 3 was 61 ± 5 days for RIT with panitumumab-DOTA- 111 In compared to 42 ± 6 days for mice treated with irrelevant IgG 2 -DOTA- 111 In ( P < 0.0001) and 35 ± 3 days for mice receiving 0.9% NaCl ( P < 0.0001). However, tumors regrew at later time points. The median survival of mice treated with panitumumab-DOTA- 111 In was 70 days versus 46 days for IgG 2 -DOTA- 111 In ( P < 0.0001) or 40 days for 0.9% NaCl ( P < 0.0001). We conclude that panitumumab-DOTA- 111 In is a promising theranostic agent for TNBC. Increasing the administered amount of panitumumab-DOTA- 111 In and/or combination with radiosensitizing PARP inhibitors used for treatment of patients with TNBC may provide a more durable response to RIT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
小新star完成签到,获得积分10
4秒前
羽辰_Ste1Lar完成签到,获得积分10
5秒前
晚风完成签到 ,获得积分10
5秒前
6秒前
jiangxiang完成签到,获得积分20
6秒前
大模型的应助被怕黑的纸鹤采纳,获得10
7秒前
zl13332完成签到 ,获得积分10
7秒前
7秒前
Zilch完成签到,获得积分10
8秒前
drhkc完成签到,获得积分10
9秒前
积极问晴完成签到,获得积分10
10秒前
YIDAN发布了新的文献求助20
10秒前
贾茜茜完成签到 ,获得积分10
10秒前
极限001的应助被Nics110采纳,获得200
11秒前
LWY完成签到 ,获得积分10
12秒前
桃子完成签到 ,获得积分10
13秒前
好幸运发布了新的文献求助10
13秒前
14秒前
医学完成签到,获得积分10
15秒前
Zilch发布了新的文献求助10
15秒前
华仔的应助被Evan采纳,获得10
15秒前
板栗南瓜完成签到 ,获得积分10
16秒前
han完成签到,获得积分10
17秒前
17秒前
17秒前
佳1完成签到,获得积分20
19秒前
19秒前
rin382完成签到,获得积分10
19秒前
1111发布了新的文献求助10
20秒前
20秒前
德力达完成签到,获得积分20
21秒前
21秒前
orixero的应助被雾里采纳,获得10
21秒前
21秒前
略略发布了新的文献求助10
22秒前
尊敬诗桃完成签到 ,获得积分10
22秒前
李健的应助被lll采纳,获得10
23秒前
26秒前
小波发布了新的文献求助30
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158391
求助须知:如何正确求助?哪些是违规求助? 9554206
关于积分的说明 21718287
捐赠科研通 7747762
什么是DOI,文献DOI怎么找? 3426964
关于科研通互助平台的介绍 2551704
邀请新用户注册赠送积分活动 2471132